Long-term sargramostim led to motor gains for 5 patients

Long-term treatment with sargramostim, an immune-modulating medication from Partner Therapeutics, was safe and improved motor function for five men with Parkinson’s disease, according to data from a small open-label Phase 1 clinical trial. Evidence suggested the therapy exerted its benefits by boosting the function of anti-inflammatory…

Low-dose Sargramostim Shows Promise in Small Early Trial

Treatment with a low dose of the immune-modulating medication sargramostim was well-tolerated and eased motor symptoms in a small clinical trial of people with Parkinson’s disease. The results “provide the basis for larger scale assessments to determine clinical efficacy of a reduced sargramostim regimen within the [Parkinson’s] population,” according…